研究单位：[1]The Second People's Hospital of Sichuan[2]Biotech Pharmaceutical Co., Ltd.[3]Gansu Province Medical Science Institute,Lanzhou,Gansu,China,730050[4]Guangxi Tumor Hospital,Nanning,Guangxi,China,530021[5]GuiZhou Cancer Hospital,Guiyang,Guizhou,China,550004[6]Neimenggu Tumor Hospital,Baotou,Neimenggu,China,014030[7]The Tumor Affiliated Hospital of Ningxia Medical University General Hospita,Yinchuan,Ningxia,China,750004[8]Qinghai Five Hospital,Xining,Qinghai,China[9]Xijing Hospital,Xi-an,Shanxi,China,710032[10]ShanXi Cancer Hospital,Xian,Shanxi,China,710061[11]The Second People's Hospital of Sichuan,Chengdu,Sichuan,China,610041[12]West China Hospital, Sichuan University,Chengdu,Sichuan,China,610041[13]Daping Hospital and the Research Institute of Surgery of the Third Military Medical University,Chongqing,Sichuan,China,400042[14]Xinjiang tumor hospital, The Third Affiliated Hospital of Xinjiang Medical University,Wulumuqi,Xinjiang,China,830000[15]Yunnan Tumor Hospital, The Third Affiliated Hospital of KUNMING Medical University,Kunming,Yunnan,China,652100
The purpose of this study is to evaluate the efficiency and safety of adding nimotuzumab to neoadjuvant and concurrent chemoradiotherapy in the treatment of patients with locoregionally advanced squamous cell carcinoma of the oropharynx and hypopharynx.
